复宏汉霖(02696.HK)获润新生物小分子抑制剂中国区许可专利
复宏汉霖(02696.HK)公布,有关就靶向人类BRAF蛋白V600E突变小分子抑制剂RX208与润新生物订立具约束力条款概要一事,今日(11日)公司与对方订立药品技术许可协议。
润新生物将基於必要或合理有用的相关许可专利及许可专有技术,授予公司一项可再许可的独家许可,供公司在许可区域内研究、开发、生产及商业化许可产品。同时,公司有权将许可产品用於任何人类适应症及任何治疗方法,包括但不限於单药、组合用药或鸡尾酒疗法。许可区域为中国(含港澳台地区)。
公司应向润新生物支付首付款合计9,750万元人民币(下同);监管及商业销售里程碑付款合计不超过10.775亿元;除根据协议条款做出的调整及/或抵扣外,以年度净销售额的8%到12%计的特许权使用费。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.